FOX vs REGN · P/E 13, rev $16.30B vs P/E 14, rev $14.34B
Fox Corp Class B (FOX) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Fox Corp Class B (FOX) is a entertainment company listed on US.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported FOX revenue for 2025-06-30 was $16.30B. Net income was $2.29B. Revenue was up 16.6% from 2024-06-30 to 2025-06-30. FOX currently screens at market cap $24.49B and trailing P/E 13.0.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
FOX currently screens at market cap $24.49B and trailing P/E 13.0. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the FOX and REGN stock pages for the full models.
Not investment advice.